Real-world comparative effectiveness study of Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs in Korean patients with rheumatoid arthritis
Authors' conclusion
In this observational real-world study of Korean patients with RA who were eligible for targeted therapy, JAKis demonstrated comparable effectiveness and safety to bDMARDs.
Study context
- Population
- Korean patients with rheumatoid arthritis (RA) with inadequate response to MTX, naive to Janus kinase inhibitors (JAKis) and biologic disease-modifying antirheumatic drugs (bDMARDs), 17 centres in the Republic of Korea
- Participants
- 506 patients
- Exposure
- JAKi vs bDMARD in RA after inadequate response to MTX
- JAKin = 253
- bDMARDn = 253reference
- Outcome
- Proportion achieving low disease activity (LDA) by DAS28-ESR
- Follow-up
- 24 weeks
Methodological detailsmulticentre, real-world, comparative effectiveness
- Multicentre
- Real-world
- Comparative effectiveness
Main finding
As reported in the abstract
LDA (DAS28-ESR)
Observational data: associations, not effects.
Secondary outcomes
Remission · 24 weeks
Safety
Exposure-adjusted event rate (EAER) of overall adverse events (AEs) (per 100 person-years) · 48 weeks
- No significant intergroup differences
Original publication
Real-world comparative effectiveness study of Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs in Korean patients with rheumatoid arthritis. Semin Arthritis Rheum. Published 14 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →